Hscs stock


Aime
Here is some information about HSCS stock:
- Recent Performance: Heart Test Laboratories (HSCS) experienced a significant decline in its stock price, with a closing price of $3.52 on August 20, 2024, representing a 95.0% decrease from the previous year. The stock has seen a downward trend in the past month, with a 52-week range between $3.03 and $85.181.
- Financial Performance: The company reported a net loss of $1.85 million and a diluted EPS of -$0.46 for the quarter ending December 31, 2024. The net income growth rate was -13.1% and the diluted EPS quarter-over-quarter growth rate was not available2.
- Valuation Metrics: The company's P/E (TTM) ratio is -0.07, indicating that the company is not currently profitable. The P/B ratio is 0.41, and the P/S ratio is 161.99, suggesting that the stock may be undervalued based on its assets and sales3.
- Insider Transactions: There have been no recent insider transactions that could indicate confidence or lack of confidence in the company's future.
- Market Position: Heart Test Laboratories is a medical technology company focused on applying AI-based technology to improve the clinical utility of an ECG. The company has a proprietary algorithm designed to detect impaired cardiac relaxation and offers a cloud-based platform to host AI-ECG solutions4.
In conclusion, HSCS stock appears to be undervalued based on its negative P/E ratio and high P/S ratio. The company's recent stock price decline and negative net income growth rate also suggest that investors may be concerned about its financial performance. However, the company's market position and focus on innovative AI-ECG solutions could offer potential for future revenue growth. Investors should closely monitor the company's financial performance and growth strategies.
Source:
1.
HSCS 52-Week High, 52-Week Low
more
less
Continue this conversation 

Explore
Screener
Analysis
Wiki